- Motley Fool•2 days ago
More good news could be on the way soon for Jazz Pharmaceuticals.
- American City Business Journals•2 days ago
There can be a flipside to biotech industry success: When a company wins regulatory approval for a potentially top-selling drug, it becomes a buyout target — and the consequences for the local real estate market can be unexpected. Take Onyx Pharmaceuticals. Kyprolis, the South San Francisco company’s treatment for the blood cancer known as multiple myeloma, won the attention of Amgen Inc., which bought Onyx in 2013 for $10 billion.
- Zacks•2 days ago
Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||165.00 x 1000|
|Ask||165.94 x 100|
|Day's Range||165.08 - 166.93|
|52 Week Range||133.64 - 184.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.19|
|Dividend & Yield||4.60 (2.78%)|
|1y Target Est||N/A|